CA2615670C - Inhibiteurs de pompe a protons isotopiquement substitues - Google Patents

Inhibiteurs de pompe a protons isotopiquement substitues Download PDF

Info

Publication number
CA2615670C
CA2615670C CA2615670A CA2615670A CA2615670C CA 2615670 C CA2615670 C CA 2615670C CA 2615670 A CA2615670 A CA 2615670A CA 2615670 A CA2615670 A CA 2615670A CA 2615670 C CA2615670 C CA 2615670C
Authority
CA
Canada
Prior art keywords
compound
methoxy
formula
difluoromethoxy
trideuteriomethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2615670A
Other languages
English (en)
Other versions
CA2615670A1 (fr
Inventor
Bernhard Kohl
Bernd Mueller
Dieter Haag
Wolfgang-Alexander Simon
Karl Zech
Michael David
Oliver Von Richter
Felix Huth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Takeda GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda GmbH filed Critical Takeda GmbH
Publication of CA2615670A1 publication Critical patent/CA2615670A1/fr
Application granted granted Critical
Publication of CA2615670C publication Critical patent/CA2615670C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA2615670A 2005-07-26 2006-07-26 Inhibiteurs de pompe a protons isotopiquement substitues Expired - Fee Related CA2615670C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05106868.2 2005-07-26
EP05106868 2005-07-26
PCT/EP2006/064666 WO2007012650A1 (fr) 2005-07-26 2006-07-26 Inhibiteurs de pompe a protons isotopiquement substitues

Publications (2)

Publication Number Publication Date
CA2615670A1 CA2615670A1 (fr) 2007-02-01
CA2615670C true CA2615670C (fr) 2015-01-20

Family

ID=35734406

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2615670A Expired - Fee Related CA2615670C (fr) 2005-07-26 2006-07-26 Inhibiteurs de pompe a protons isotopiquement substitues

Country Status (17)

Country Link
EP (1) EP1910293A1 (fr)
JP (1) JP5448448B2 (fr)
KR (1) KR101358509B1 (fr)
CN (2) CN101268051B (fr)
AR (1) AR054584A1 (fr)
AU (1) AU2006274036B2 (fr)
BR (1) BRPI0614039A2 (fr)
CA (1) CA2615670C (fr)
EA (1) EA016814B1 (fr)
HK (2) HK1125098A1 (fr)
IL (1) IL188773A (fr)
MX (1) MX2008000901A (fr)
NO (1) NO20080839L (fr)
NZ (1) NZ565078A (fr)
TW (1) TWI394750B (fr)
WO (1) WO2007012650A1 (fr)
ZA (1) ZA200800303B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101268050B (zh) * 2005-07-26 2012-11-28 奈科明有限责任公司 同位素取代的泮托拉唑
WO2007041630A1 (fr) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Inhibiteurs deutériés d'atpase h+,k+ gastrique ayant des propriétés thérapeutiques renforcées
US20080255200A1 (en) * 2007-04-11 2008-10-16 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
WO2008127640A2 (fr) * 2007-04-11 2008-10-23 Auspex Pharmaceuticals, Inc. Benzimidazoles substitués
KR20120114356A (ko) 2010-02-12 2012-10-16 에스티브 퀴미카 에스.에이. 에스오메프라졸 나트륨염의 제조공정
CN104530003A (zh) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPH0643426B2 (ja) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
BR9507200A (pt) * 1994-03-25 1997-09-16 Isotechnika Inc Melhora da eficácia de drogas por deuteração
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
NO309305B1 (no) * 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater
DE10123129A1 (de) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
DE10162121A1 (de) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
CN101268050B (zh) * 2005-07-26 2012-11-28 奈科明有限责任公司 同位素取代的泮托拉唑

Also Published As

Publication number Publication date
AU2006274036B2 (en) 2012-05-24
EA016814B1 (ru) 2012-07-30
HK1160126A1 (en) 2012-08-10
WO2007012650A1 (fr) 2007-02-01
TWI394750B (zh) 2013-05-01
MX2008000901A (es) 2008-03-26
NO20080839L (no) 2008-02-18
AU2006274036A1 (en) 2007-02-01
HK1125098A1 (en) 2009-07-31
CA2615670A1 (fr) 2007-02-01
TW200714596A (en) 2007-04-16
IL188773A (en) 2014-02-27
AR054584A1 (es) 2007-06-27
KR20080037676A (ko) 2008-04-30
CN101268051B (zh) 2011-08-31
AU2006274036A2 (en) 2008-03-20
CN102134232A (zh) 2011-07-27
EP1910293A1 (fr) 2008-04-16
EA200800203A1 (ru) 2008-08-29
JP2009502871A (ja) 2009-01-29
CN101268051A (zh) 2008-09-17
BRPI0614039A2 (pt) 2011-03-09
JP5448448B2 (ja) 2014-03-19
ZA200800303B (en) 2009-01-28
CN102134232B (zh) 2012-11-21
NZ565078A (en) 2010-03-26
IL188773A0 (en) 2008-08-07
KR101358509B1 (ko) 2014-02-05

Similar Documents

Publication Publication Date Title
CA2615678C (fr) Pantoprazole substitue d'un point de vue isotopique
EP0654471B1 (fr) Dérivés de pyridine, compositions pharmaceutiques les contenant, leur utilisation pour le préparation de médicaments de valeur thérapeutique ou préventive et procédé pour leur préparation
AU2011211306B2 (en) Di - substituted pyridine derivatives as anticancers
IE58363B1 (en) Pyridine derivatives and their production
CA2615670C (fr) Inhibiteurs de pompe a protons isotopiquement substitues
NO841754L (no) Fremgangsmaate ved fremstilling av nye fluoralkoksyforbindelser
US5708013A (en) Pyridine derivative and therapeutic agent for ulcer comprising the same
WO2000020391A1 (fr) Derives pyridine disubstitues en position 2,3, procede de preparation associe, compositions de medicament contenant ces derives, et intermediaires servant dans cette preparation
JPH05117268A (ja) ピリジン化合物
US7601737B2 (en) Isotopically substituted proton pump inhibitors
WO1997032854A1 (fr) Derives de 2-sulfinylnicotinamide, intermediaire de ces derives, procede pour produire ces derives et composition medicinale contenant ces derives comme ingredient actif
JP2718945B2 (ja) ピリジン誘導体及びそれを含有する潰瘍治療剤
US20070219236A1 (en) Dialkoxy-Imidazopyridines Derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160726